Related Experiment Video
Updated: Aug 6, 2026
09:02
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Enhancing Optogenetics-Based Cancer Therapy Via Nanotechnology
Honggang Shen1,2, Wenzhe Yi1,3, Rongzhang Li1,3
1State Key Laboratory of Drug Research & Center of Pharmaceutics Shanghai Institute of Materia Medica Chinese Academy of Sciences Shanghai China.
Exploration (Beijing, China)
|July 24, 2026
Summary
Optogenetics combined with nanotechnology offers new precision cancer therapies. This approach improves delivery and tissue penetration for engineered living therapeutics, overcoming current treatment limitations.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapy
Background:
- Optogenetics enables precise control of cellular behavior for cancer treatment.
- Clinical applications are hindered by poor delivery of optogenetic tools and limited light penetration in tissues.
Purpose of the Study:
- To explore how nanotechnology can overcome the limitations of optogenetics in cancer therapy.
- To discuss the development of engineered living therapeutics using optogenetics and nanotechnology.
Main Methods:
- Utilizing nanoscale drug delivery systems for targeted optogenetic tool delivery.
- Employing light-conversion nanomaterials for deep-tissue activation.
- Integrating nanotechnology with optogenetics for engineered living therapeutics (immune cells, bacteria).
Main Results:
- Nanotechnology enhances targeted delivery and deep-tissue penetration for optogenetics.
- Engineered living therapeutics demonstrate programmable, localized antitumor responses.
- Preclinical studies show promise but highlight challenges in biosafety and immunogenicity.
Conclusions:
- The synergy between optogenetics and nanotechnology presents a powerful strategy for precision cancer treatment.
- Further interdisciplinary research is needed to address challenges and advance clinical viability.
- This integrated approach promises to overcome barriers in current cancer therapies for personalized treatment.
